, Tracking Stock Market Picks
Enter Symbol:
Rating: RXII
Buy $5

galena biopharma (NASDAQ: GALE) reiterated to Buy with price target $5 by MLV & Co

Thursday,  Nov 20, 2014  8:25 AM ET by Lynn Gilbert

MLV & Co reiterated galena biopharma (NASDAQ: GALE) to Buy with price target
$5. Previously, MLV & Co rated galena biopharma (NASDAQ: GALE) to Buy with price target $6 on 10/25/2012, when the stock price was valued at $2.04.

RXi Pharmaceuticals Corporation (RXi) is a discovery-stage biopharmaceutical company pursuing therapeutics based on ribonucleic acid interference (RNAi) for the treatment of human diseases. The Company is focused on internal research and development programs on certain inflammatory and metabolic diseases, and to pursue other therapeutic areas with potential partners. RXi commenced operations after CytRx Corporation contributed to the Company its portfolio of RNAi therapeutic assets, which consisted primarily of RNAi licenses and related intellectual property, and a nominal amount of equipment. As of December 31, 2008, the Company had not generated any revenues.

MLV & Co is a boutique investment bank and institutional broker-dealer focused on providing independent financial advice and unique capital markets expertise to corporate and institutional clients in capital intensive industries such as metals and mining, life sciences, energy and real estate. With a focus on raising money efficiently for clients, MLV has rapidly become a leader in the At-the-Market(ATM) transaction market.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy